Vascular Anomalies
9
2
6
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs
Institutional Registry of Rare Diseases
Trametinib Treatment for Complicated Vascular Anomalies
Radiofrequency Ablation of Vascular Anomalies
Safety and Efficacy Of Amber Peripheral Liquid Embolic System
Efficacy and Safety of Rapamycin to Complex Vascular Anomalies in Pediatric Patients
Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.